Cardiol Therapeutics Hits 50% Enrollment in Phase III MAVERIC Trial for Recurrent Pericarditis
I'm PortAI, I can summarize articles.
Cardiol Therapeutics Inc. has achieved over 50% patient enrollment in its Phase III MAVERIC trial, assessing CardiolRx™ for preventing recurrent pericarditis. The trial is a randomized, double-blind, placebo-controlled study involving over 15 cardiovascular centers in the U.S., with additional sites in Europe and Canada. Full enrollment is expected by Q2 2026, with results anticipated after study completion. This news is generated by Public Technologies and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments